StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
AWHL

Aspira Women's Health Inc.

AWHL OTC In Vitro & In Vivo Diagnostic Substances EDGAR ↗
$0.35
+0.02 +6.06%

Key statistics

from XBRL data in SEC filings
Market cap
$15.2M
Revenue (TTM)
$8.90M
Net income (TTM)
$2.52M
EPS (TTM)
$-0.33
P/E ratio
Dividend yield
Free cash flow
-$7.04M
Cash
$1.34M
Total assets
$5.09M
Gross margin
60.9%
52-week range
$0.18 – $0.71

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Entered a material agreement; Took on a direct financial obligation Jul 15, 2026 8-K/A Director or officer change Jul 7, 2026 8-K Director or officer change Jun 22, 2026 8-K Shareholder vote results Jun 17, 2026 8-K Entered a material agreement; Unregistered sale of equity Jun 9, 2026 8-K Entered a material agreement May 26, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 8-K Director or officer change Apr 30, 2026 10-K Fiscal year ended 2025-12-31 Apr 1, 2026 8-K/A Entered a material agreement Mar 25, 2026 8-K Entered a material agreement; Took on a direct financial obligation Jan 30, 2026 8-K Regulation FD disclosure Dec 31, 2025 8-K Entered a material agreement; Unregistered sale of equity Dec 23, 2025 8-K Entered a material agreement Dec 22, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Results of operations (earnings release) Nov 14, 2025 8-K/A Entered a material agreement; Unregistered sale of equity Nov 3, 2025 8-K Other events Oct 15, 2025 8-K Entered a material agreement; Unregistered sale of equity Sep 25, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Sep 18, 2025 8-K Director or officer change Sep 3, 2025 8-K Results of operations (earnings release) Aug 13, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Director or officer change Jul 15, 2025 8-K Other events Jun 11, 2025 8-K Shareholder vote results Jun 4, 2025 10-Q Quarter ended 2025-03-31 May 19, 2025 8-K Results of operations (earnings release) May 19, 2025 8-K Delisting notice or listing-rule failure Apr 16, 2025 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Other events Apr 8, 2025 8-K Amended charter or bylaws Mar 31, 2025 8-K Director or officer change Mar 31, 2025 10-K Fiscal year ended 2024-12-31 Mar 27, 2025 8-K Results of operations (earnings release) Mar 27, 2025 8-K Director or officer change Mar 25, 2025 8-K Director or officer change Mar 19, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Mar 11, 2025 8-K Delisting notice or listing-rule failure Feb 14, 2025 8-K Director or officer change Feb 10, 2025 8-K Director or officer change Jan 31, 2025